Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Thursday broker round-up

Thu, 30th Apr 2020 13:16

(Sharecast News) - Mitchells & Butlers: JP Morgan upgrades to overweight with a target price of 340p.



Plus500: Berenberg reiterates hold with a target price of 1,120p.

Elementis: Berenberg reiterates buy with a target price of 100p.

Synthomer: Berenberg reiterates buy with a target price of 330p.

Brewin Dolphin: Canaccord reiterates buy with a target price of 335p.

Grafton Group: Canaccord reiterates buy with a target price of 725p.

IMI: Deutsche Bank reiterates buy with a target price of 1,000p.

Compass Group: Deutsche Bank reiterates hold with a target price of 1,506p.

AstraZeneca: Liberum reiterates buy with a target price of 8,870p.

Rightmove: Liberum reiterates hold with a target price of 470p.

Hurricane Energy: RBC Capital Markets reiterates outperform with a target price of 30p.

Restaurant Group: Citigroup reiterates outperform with a target price of 30p.

TUI: Citigroup reiterates sell with a target price of 125p.

Rio Tinto: JP Morgan reiterates neutral with a target price of 4,730p.

Intertek Group: Credit Suisse reiterates neutral with a target price of 4,400p.

Related Shares

More News
Today 08:40

TOP NEWS: AstraZeneca's Tagrisso plus chemo gets approval in China

(Alliance News) - AstraZeneca PLC on Wednesday celebrated the approval of Tagrisso plus chemotherapy for a cancer form in China, a day after a similar...

25 Jun 2024 09:05

TOP NEWS: AstraZeneca details mixed findings from cancer drug trials

(Alliance News) - AstraZeneca PLC on Tuesday announced a mixed bag of results for two of its leading cancer drugs Imfinzi and Tagrisso.

25 Jun 2024 07:48

LONDON BRIEFING: Mixed bag for Astra drug; Landsec ups Bluewater stake

(Alliance News) - London's FTSE 100 is set to tread water on Tuesday, with a slump for US tech shares overnight keeping a lid on enthusiasm.

25 Jun 2024 07:17

AstraZeneca posts mixed results from recent Imfinzi trials

(Sharecast News) - AstraZeneca announced contrasting results from two phase three trials involving its immunotherapy drug 'Imfinzi', or durvalumab, on...

24 Jun 2024 15:40

US Supreme Court gives pharma companies a chance to thwart terrorism-funding lawsuit

WASHINGTON, June 24 (Reuters) - The U.S. Supreme Court gave a boost on Monday to a challenge by 21 pharmaceutical and medical equipment companies le...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.